Prof. Stephen J. Schuster | ICML 2017 | Interim results of the JULIET trial of CTL019 in R/R DLBCL

By Anne Villeneuve, Stephanie Hill

Jun 19, 2017

Interim results of the JULIET trial of CTL019 in R/R DLBCL

More about...

Aggressive B-cell lymphomas Diffuse large B-cell lymphoma ICML 2017 JULIET Tisagenlecleucel

Tisagenlecleucel in patients with R/R DLBCL without measurable disease at infusion

Tisagenlecleucel (tis) demonstrates efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) without detectable disease after bridging...

Aug 16, 2019

Tisagenlecleucel in patients with R/R DLBCL without measurable disease at infusion

Tisagenlecleucel (tis) demonstrates efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma...

Aug 16, 2019

EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 2 – Allo-SCT

A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took place on Tuesday 26 March 2019, during the 45th...

Apr 4, 2019

EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 2 – Allo-SCT

A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took...

Apr 4, 2019

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Stephen J. Schuster | ICML 2017 | Interim results of the JULIET trial of CTL019 in R/R DLBCL

By Anne Villeneuve, Stephanie Hill

Jun 19, 2017

More about...

Related articles

Aug 16, 2019

Aug 16, 2019

Apr 4, 2019

Apr 4, 2019

Newsletter